Biogen posts long-term Phase 3 data for Alzheimer’s therapy
travellinglight/iStock via Getty Images


Biogen (NASDAQ:BIIB) is trading ~3% higher in the pre-market Wednesday after announcing long-term data from two Phase 3 trials for the Alzheimerâs therapy Aduhelm developed in partnership with the Japanese pharma company, Eisai (OTCPK:ESALF)
(OTCPK:ESALY).
Following nearly two and half years of intravenous Aduhelm at 100 mg/mL dose, the patients in the long-term extension phase of the Phase 3 trials continued to demonstrate âsignificant reductionsâ in two key hallmarks of the disease: amyloid-beta plaques and plasma p-tau181.

At week 78, the patients with reduced levels of plasma p-tau181 had a lower clinical decline compared to patients whose p-tau181 levels were not reduced, the company said.
âThese data demonstrate that long-term treatment with ADUHELM continues to reduce the underlying pathologies of Alzheimerâs disease beyond two years," noted Samantha Budd Haeberlein, Head of Neurodegeneration Development at Biogen (BIIB).
Data were part of a presentation at the ongoing International Conference on Alzheimerâs and Parkinsonâs Diseases (AD/PD 2022). 
Read: Biogen (BIIB) awaits key Medicare decision on Aduhelm next month amid growing public pressure for its coverage.